+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904662
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-obesity Prescription Drugs Market is projected to reach USD 7.84 Billion in 2026. It is expected to continue growing at a CAGR of 8.40%, reaching USD 12.77 Billion by 2032.

Anti-obesity prescription drugs have moved from adjunctive weight-loss aids to core therapies for chronic weight management and cardiometabolic risk reduction. The landscape is being reshaped by incretin-based medicines, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, supported by large clinical programs showing clinically meaningful weight reduction and improvements in metabolic markers.

The demand backdrop is substantial and data-backed: the World Health Organization reported that, in 2022, more than 1 billion people were living with obesity, including over 890 million adults, while 2.5 billion adults were overweight. As health systems connect obesity with type 2 diabetes, cardiovascular disease, sleep apnea, fatty liver disease, and musculoskeletal disorders, prescription anti-obesity medications are increasingly positioned as long-term medical interventions rather than cosmetic treatments.

Transformative Shifts in the Market Landscape

The landscape is shifting from older appetite suppressants and absorption inhibitors toward hormone-based therapies with stronger efficacy profiles. Semaglutide 2.4 mg demonstrated about 15% mean body-weight reduction in pivotal STEP trials, while tirzepatide produced weight reductions exceeding 20% in major SURMOUNT studies, establishing new benchmarks for obesity pharmacotherapy.

At the same time, payers, regulators, employers, and healthcare providers are reassessing access because obesity treatment creates near-term pharmacy cost pressure alongside potential long-term reductions in cardiometabolic complications. Competitive strategy is now centered on differentiation in efficacy, tolerability, dosing convenience, cardiovascular outcomes, oral formulations, manufacturing scale, and real-world evidence that supports reimbursement for chronic use.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across anti-obesity drug discovery, clinical development, manufacturing, and commercialization. AI-enabled target discovery, molecular modeling, trial-site selection, and patient stratification can help sponsors identify responder profiles, optimize study design, and improve the probability of technical and regulatory success.

In commercialization and operations, AI supports demand planning, supply-chain visibility, adherence monitoring, pharmacovigilance, and real-world evidence generation. This is especially important for GLP-1 and incretin therapies, where high demand, complex biologics manufacturing, cold-chain logistics, and long-term persistence influence performance. Responsible deployment requires strong governance around data quality, privacy, bias mitigation, safety monitoring, and transparent clinical decision support.

Key Regional Insights

North America remains the most advanced commercial region for anti-obesity prescription drugs, led by the United States, where FDA-approved therapies, specialist prescribing, broad clinical awareness, and employer health-benefit debates are accelerating adoption. Canada is also seeing rising clinical interest, although reimbursement rules, formulary controls, and provincial access pathways shape the pace of use.

Europe is a highly evidence-driven region where the European Medicines Agency, national health technology assessment bodies, clinical guidelines, and payer negotiations influence the speed and breadth of uptake. Asia-Pacific carries major long-term treatment relevance because China, India, Japan, South Korea, Australia, and ASEAN economies face rising obesity, diabetes, and metabolic syndrome burdens, although affordability and reimbursement remain uneven. Latin America, led by Brazil and Mexico, is supported by high obesity prevalence and expanding private-sector demand. The Middle East, particularly Gulf countries, faces one of the world’s highest cardiometabolic disease burdens, while Africa remains earlier in adoption, with access concentrated in urban private care and shaped by affordability, supply availability, cold-chain capacity, and competing public-health priorities.

Key Group Insights

G7 markets are setting the global direction for evidence standards, reimbursement debates, cardiovascular outcomes data, obesity clinical guidelines, and premium access expectations for anti-obesity prescription drugs. The European Union adds a centralized regulatory framework through regional authorization processes, but fragmented national access decisions make country-level health technology assessment, budget impact review, and payer negotiation essential for market entry.

BRICS countries represent the largest emerging demand pool because of population scale, urbanization, and increasing obesity-related diabetes, but affordability, local manufacturing policy, medicine availability, and public reimbursement constraints remain decisive. ASEAN markets show growing private-sector demand in urban centers as lifestyle-related metabolic disorders rise, while GCC countries are highly relevant due to elevated obesity and diabetes prevalence, high healthcare spending, and national prevention strategies. NATO countries overlap with many high-income pharmaceutical markets, where medicine security, supply resilience, cold-chain reliability, and cross-border regulatory alignment are becoming increasingly important for anti-obesity pharmacotherapy access.

Key Country Insights

The United States is the leading market for GLP-1 and dual incretin anti-obesity medicines, supported by FDA approvals, high clinical awareness, specialist and primary-care prescribing, and strong patient demand, but constrained by payer utilization management, coverage exclusions, prior authorization, and out-of-pocket costs. Canada is progressing through specialist-led adoption and guideline-driven care, while Mexico and Brazil combine high obesity prevalence with uneven reimbursement, expanding private demand, and growing recognition of obesity as a chronic disease requiring medical treatment.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by national payer assessments, obesity service capacity, prescribing controls, and evidence of cost-effectiveness, while Russia remains more dependent on local access dynamics, regulatory pathways, and medicine availability. China and India offer major long-term treatment relevance because of large populations and rising metabolic disease, with affordability and access infrastructure remaining central considerations. Japan and South Korea emphasize regulated medical adoption, safety monitoring, and obesity-related comorbidity management, while Australia benefits from established obesity care pathways, specialist prescribing, and strong awareness of cardiometabolic risk reduction.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence beyond weight loss, including cardiovascular outcomes, diabetes prevention, sleep apnea, kidney outcomes, liver health, quality of life, safety, and treatment persistence data. Building payer-ready evidence packages is essential as health systems evaluate chronic therapy costs against long-term reductions in obesity-related complications.

Organizations should also invest in scalable manufacturing, supply-chain resilience, cold-chain quality, patient-support programs, adherence tools, and real-world evidence platforms. Competitive advantage will increasingly come from oral or less frequent dosing, improved tolerability, personalized treatment pathways, responsible AI use, and partnerships with employers, providers, pharmacies, and digital health platforms to improve persistence and measurable outcomes.

Research Methodology

The executive summary is based on a structured review of verified public-domain evidence, including regulatory approvals and prescribing labels from the FDA and EMA, clinical trial registries, peer-reviewed trial publications, World Health Organization obesity statistics, national public-health sources, treatment guidelines, and publicly disclosed clinical development updates.

The methodology emphasizes triangulation across epidemiology, regulatory status, clinical efficacy, safety, reimbursement dynamics, access conditions, and regional healthcare infrastructure. Insights were synthesized qualitatively to identify strategic implications for anti-obesity prescription drugs without relying on unverified market-size claims, market share statements, or unsupported forecasts.

Conclusion

Anti-obesity prescription drugs are entering a new phase defined by high-efficacy incretin therapies, expanding clinical evidence, and stronger recognition of obesity as a chronic disease requiring medical management. The category is no longer limited to weight reduction; it is increasingly linked to cardiometabolic risk management, comorbidity prevention, and long-term health-system value.

Future leadership will depend on proof of durable outcomes, equitable access, manufacturing reliability, payer engagement, responsible AI integration, and innovation that improves tolerability and convenience. Organizations that combine clinical rigor with responsible commercialization will be best positioned in the evolving global obesity pharmacotherapy landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-obesity Prescription Drugs Market, by Drug Class
7.1. GLP-1 Agonists
7.1.1. Liraglutide
7.1.2. Semaglutide
7.2. Setmelanotide
7.3. Orlistat
7.4. Tirzepatide
8. Anti-obesity Prescription Drugs Market, by Dosage Form
8.1. Injectables
8.2. Orals
8.2.1. Capsules
8.2.2. Tablets
9. Anti-obesity Prescription Drugs Market, by Therapy Type
9.1. Monotherapy
9.2. Combination Therapy
10. Anti-obesity Prescription Drugs Market, by Application
10.1. Core Obesity / Overweight Management
10.2. Pediatric Obesity Management
10.3. Precision-Obesity Applications
11. Anti-obesity Prescription Drugs Market, by End User
11.1. Ambulatory Care Centers
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
11.4.1. Endocrinology Clinics
11.4.2. General Practice Clinics
11.4.3. Weight Loss Clinics
12. Anti-obesity Prescription Drugs Market, by Distribution Channel
12.1. Offline
12.2. Online
13. Asia-Pacific Anti-obesity Prescription Drugs Market
14. North America Anti-obesity Prescription Drugs Market
15. Latin America Anti-obesity Prescription Drugs Market
16. Europe Anti-obesity Prescription Drugs Market
17. Middle East Anti-obesity Prescription Drugs Market
18. Africa Anti-obesity Prescription Drugs Market
19. ASEAN Anti-obesity Prescription Drugs Market
20. GCC Anti-obesity Prescription Drugs Market
21. European Union Anti-obesity Prescription Drugs Market
22. BRICS Anti-obesity Prescription Drugs Market
23. G7 Anti-obesity Prescription Drugs Market
24. NATO Anti-obesity Prescription Drugs Market
25. United States Anti-obesity Prescription Drugs Market
26. Canada Anti-obesity Prescription Drugs Market
27. Mexico Anti-obesity Prescription Drugs Market
28. Brazil Anti-obesity Prescription Drugs Market
29. United Kingdom Anti-obesity Prescription Drugs Market
30. Germany Anti-obesity Prescription Drugs Market
31. France Anti-obesity Prescription Drugs Market
32. Russia Anti-obesity Prescription Drugs Market
33. Italy Anti-obesity Prescription Drugs Market
34. Spain Anti-obesity Prescription Drugs Market
35. China Anti-obesity Prescription Drugs Market
36. India Anti-obesity Prescription Drugs Market
37. Japan Anti-obesity Prescription Drugs Market
38. Australia Anti-obesity Prescription Drugs Market
39. South Korea Anti-obesity Prescription Drugs Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Alizyme Limited
41.2. Amgen Inc.
41.3. AstraZeneca PLC
41.4. BioCon Limited
41.5. Boehringer Ingelheim International GmbH
41.6. CHEPLAPHARM Arzneimittel GmbH
41.7. Currax Pharmaceuticals LLC
41.8. Eli Lilly and Company
41.9. F. Hoffmann-La Roche Ltd.
41.10. GlaxoSmithKline PLC
41.11. Hangzhou Sciwind Biosciences Co., Ltd.
41.12. Hanmi Pharm.Co., Ltd.
41.13. HK inno.N Corporation
41.14. Innovent Biologics, Inc.
41.15. Merck & Co., Inc.
41.16. Novo Nordisk A/S
41.17. Orexigen Therapeutics, Inc.
41.18. Pfizer Inc.
41.19. Reddy’s Laboratories Limited
41.20. Rhythm Pharmaceuticals, Inc.
41.21. Takeda Pharmaceutical Company Limited
41.22. Teva Pharmaceuticals Company Limited
41.23. Verdiva Pharma Inc.
41.24. Viking Therapeutics
41.25. Vivus LLC
41.26. Zealand Pharma A/S
41.27. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LIRAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LIRAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LIRAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SEMAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SEMAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SEMAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SETMELANOTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SETMELANOTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SETMELANOTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ORLISTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ORLISTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ORLISTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TIRZEPATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TIRZEPATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL TIRZEPATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ORALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ORALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ORALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CORE OBESITY / OVERWEIGHT MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CORE OBESITY / OVERWEIGHT MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CORE OBESITY / OVERWEIGHT MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PRECISION-OBESITY APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PRECISION-OBESITY APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PRECISION-OBESITY APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL WEIGHT LOSS CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL WEIGHT LOSS CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL WEIGHT LOSS CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 119. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 120. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 121. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 122. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 125. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 138. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 139. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 140. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 141. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 142. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 143. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 145. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 148. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 149. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 150. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 151. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 152. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 153. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 155. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 157. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 158. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 159. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 160. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 161. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 162. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 163. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 165. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 178. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 179. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 180. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 181. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 182. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 183. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 185. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 187. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 188. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 189. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 190. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 191. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 192. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 193. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 195. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 197. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 198. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 199. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 200. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 201. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 202. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 203. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 205. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 217. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 219. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 220. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 221. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 222. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 223. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 225. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 228. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 229. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 230. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 231. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 232. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 233. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 235. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 238. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 239. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 240. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 241. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 242. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 243. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 245. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 256. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 257. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 258. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 259. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 260. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 261. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 262. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 263. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 265. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 267. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 268. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 269. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 270. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 271. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 272. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 273. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 275. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 277. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 278. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 279. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 280. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 281. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 282. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 283. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 284. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 285. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 286. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 287. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 288. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 289. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 290. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 291. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 292. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 293. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 295. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 296. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 297. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 298. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 299. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 300. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 301. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 302. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 303. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 304. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 305. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 306. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 307. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 308. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 309. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 310. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 311. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 312. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 313. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 314. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 315. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 316. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 317. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 318. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 319. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 320. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 321. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 322. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 323. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 324. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 325. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 326. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 327. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 328. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 329. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 330. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 331. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 332. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY

Companies Mentioned

The companies featured in this Anti-obesity Prescription Drugs market report include:
  • Alizyme Limited
  • Amgen Inc.
  • AstraZeneca PLC
  • BioCon Limited
  • Boehringer Ingelheim International GmbH
  • CHEPLAPHARM Arzneimittel GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann‑La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hangzhou Sciwind Biosciences Co., Ltd.
  • Hanmi Pharm.Co., Ltd.
  • HK inno.N Corporation
  • Innovent Biologics, Inc.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Reddy’s Laboratories Limited
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Company Limited
  • Verdiva Pharma Inc.
  • Viking Therapeutics
  • Vivus LLC
  • Zealand Pharma A/S
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages184
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.84 Billion
Forecasted Market Value ( USD ) by 2032 $ 12.77 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032 - Product Image

Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Weight Loss and Obesity Management Market Report 2026 - Product Image

Weight Loss and Obesity Management Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Deoxycholic Acid Obesity Drugs Market Report 2026 - Product Image

Deoxycholic Acid Obesity Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032 - Product Image

Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032

  • Report
  • 358 Pages
  • Global
From

About the Anti Obesity Prescription Drugs Market

The Anti-Obesity Prescription Drugs market is a segment of the healthcare industry focused on the development, production, and marketing of medication designed to combat obesity. These medications are intended for individuals who are unable to achieve weight loss through diet and exercise alone. Anti-obesity drugs work through various mechanisms, including appetite suppression, increased energy expenditure, and decreased nutrient absorption. The market encompasses a variety of drug classes, such as lipase inhibitors, serotonin receptor agonists, and others, each targeting different pathways related to weight regulation. The use of anti-obesity prescription drugs is typically recommended for those with a body mass index (BMI) above a certain threshold or for overweight individuals with weight-related health conditions such as diabetes or high blood pressure. The development of these pharmacological agents is guided by stringent regulatory standards to ensure their efficacy and safety. Market players invest in research and development to introduce more effective treatments with fewer side effects, as obesity remains a leading health concern. Several companies are key contributors to the Anti-Obesity Prescription Drugs market. Some of the well-known players include Novo Nordisk, GlaxoSmithKline, Roche, and Vivus, Inc. These companies are involved in manufacturing FDA-approved prescription drugs and are engaged in ongoing research to improve existing treatments and bring new solutions to the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.